Following on from information provided to NICE by the company in June 2021, the appraisal of Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.